Josh Peterson

When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing. Read More

With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes. Read More

A national study is seeking to determine whether genetic testing can help physicians choose the best drugs for their patients to relieve pain and depression. Read More

Vanderbilt University Medical Center (VUMC) has expanded and relaunched genetic testing to predict patient responses to drugs. Read More

A new clinical implementation study from Vanderbilt University Medical Center measures how physicians have responded to the introduction of routine genetic testing to predict patient response to the commonly prescribed antiplatelet drug clopidogrel. Read More

A new program being offered this fall through Vanderbilt University School of Medicine will offer health care professionals the opportunity to earn a master’s degree in the growing biomedical informatics field. Read More

A research team led by Josh Peterson, M.D., MPH, assistant professor of Biomedical Informatics and Medicine, and John Graves, Ph.D., assistant professor of Preventive Medicine, will study the cost-effectiveness of testing patients’ risk of adverse gene-drug interactions. Read More

The U.S. Centers for Disease Control and Prevention has awarded Vanderbilt researchers a two-year, $1 million grant to Vanderbilt to develop a model for applying genomic testing to drug prescribing in “real-world” settings. Read More